Skip to content

The Neuroprotective Effect of Remote Ischemic Conditioning in Ruptured Aneurysm Coiling Therapy

The Neuroprotective Effect of Remote Ischemic Conditioning in Ruptured Aneurysm Coiling Therapy

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03561311
Acronym
NEAT-2
Enrollment
210
Registered
2018-06-19
Start date
2018-10-06
Completion date
2019-06-30
Last updated
2018-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysm, Ruptured, Coiling Therapy

Brief summary

The overall incidence of DWI positive for thromboembolic events following endovascular treatment of intracranial aneurysms is proximately 50%. Whether remote ischemic conditioning was safe and effective to reduce ischemic brain lesions on DWI after endovascular treatment of intracranial aneurysms is still unclear. The investigators' hypothesis is that remote ischemic conditioning is a safe and effective strategy to reduce new ischemic lesions in intracranial aneurysms patients undergoing endovascular treatment.

Interventions

DEVICEremote ischemic conditioning

Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)

DEVICEsham remote ischemic conditioning

Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg

Sponsors

Capital Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Ruptured brain aneurysm deemed suitable for neuroendovascular repair * Normal baseline brain MRI * Female subjects of childbearing potential have a negative pregnancy test. * Signed informed consent prior to entering study

Exclusion criteria

* Dissecting or mycotic brain aneurysm. * Planned endovascular vessel sacrifice as the primary modality for aneurysm treatment * Renal insufficiency with creatinine ≥ 265 umol/L * Severe, sustained hypertension (SBP \> 185 mmHg or DBP \> 110 mmHg) * Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs * Pre-morbid modified Rankin scale score of greater than 1 * Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations Patients who are unable to have an MRI scan for any reason. * Currently participating or previously participated in any investigational drug or device study within 6 months.

Design outcomes

Primary

MeasureTime frameDescription
The presence of ≥1 new brain lesions on DWIwithin 72 hours after endovascular treatmentAssessed by DWI

Secondary

MeasureTime frameDescription
Number of new ischemic lesionswithin 72 hours after endovascular treatment
Volume of new ischemic lesionswithin 72 hours after endovascular treatment
National Institutes of Health Stroke Scale7 days or dischargeScores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.
Nondisabling events30 daysScores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.National Institutes of Health Stroke Scale ≤3 or TIA is defined as nondisabling events The present subarachnoid hemorrhage isn't included.
Modified Rankin Scale30 daysScores on the modified Rankin scale of functional disability range from 0 (no symptoms) to 6 (death).
Composite of Cerebrovascular events30 daysThis is a composited endpoint.Cerebrovascular events included ischemic stroke, hemorrhagic stroke, and TIA. The present subarachnoid hemorrhage isn't included.

Other

MeasureTime frameDescription
Occurrence of adverse events and serious adverse events30 daysOccurrence of adverse events and serious adverse events

Countries

China

Contacts

Primary ContactXunming Ji, MD
jixm@ccmu.edu.cn008601083198930

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026